Wedbush Has Bullish Estimate for BCRX Q2 Earnings

BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) – Wedbush boosted their Q2 2026 EPS estimates for shares of BioCryst Pharmaceuticals in a research report issued to clients and investors on Monday, June 30th. Wedbush analyst L. Chico now anticipates that the biotechnology company will post earnings per share of $0.23 for the quarter, up from their previous estimate of $0.14. Wedbush currently has a “Outperform” rating and a $18.00 target price on the stock. The consensus estimate for BioCryst Pharmaceuticals’ current full-year earnings is ($0.36) per share. Wedbush also issued estimates for BioCryst Pharmaceuticals’ Q3 2026 earnings at $0.18 EPS, FY2026 earnings at $0.84 EPS and FY2028 earnings at $0.96 EPS.

A number of other brokerages have also recently commented on BCRX. Bank of America lifted their target price on shares of BioCryst Pharmaceuticals from $13.00 to $15.00 and gave the stock a “buy” rating in a research report on Tuesday. Barclays lifted their target price on shares of BioCryst Pharmaceuticals from $8.00 to $11.00 and gave the stock an “equal weight” rating in a research report on Wednesday, May 7th. Cantor Fitzgerald started coverage on shares of BioCryst Pharmaceuticals in a research report on Tuesday, April 29th. They issued an “overweight” rating and a $20.00 price objective on the stock. HC Wainwright restated a “buy” rating and issued a $30.00 price objective on shares of BioCryst Pharmaceuticals in a research report on Tuesday, May 6th. Finally, Royal Bank Of Canada restated an “outperform” rating and issued a $13.00 price objective on shares of BioCryst Pharmaceuticals in a research report on Monday, June 30th. One investment analyst has rated the stock with a hold rating and ten have issued a buy rating to the stock. Based on data from MarketBeat.com, BioCryst Pharmaceuticals presently has an average rating of “Moderate Buy” and a consensus price target of $16.70.

BioCryst Pharmaceuticals Stock Down 0.8%

Shares of NASDAQ:BCRX opened at $8.95 on Thursday. The stock has a market cap of $1.87 billion, a PE ratio of -34.40, a PEG ratio of 2.55 and a beta of 1.04. The company’s fifty day moving average is $10.06 and its 200 day moving average is $8.60. BioCryst Pharmaceuticals has a 52 week low of $6.02 and a 52 week high of $11.31.

Institutional Inflows and Outflows

Several hedge funds and other institutional investors have recently made changes to their positions in the company. Millennium Management LLC lifted its position in BioCryst Pharmaceuticals by 382.6% during the first quarter. Millennium Management LLC now owns 3,812,874 shares of the biotechnology company’s stock valued at $28,597,000 after purchasing an additional 3,022,769 shares during the period. Vanguard Group Inc. increased its holdings in BioCryst Pharmaceuticals by 7.8% during the fourth quarter. Vanguard Group Inc. now owns 21,890,422 shares of the biotechnology company’s stock valued at $164,616,000 after buying an additional 1,583,826 shares during the last quarter. Eversept Partners LP lifted its position in BioCryst Pharmaceuticals by 269.9% during the fourth quarter. Eversept Partners LP now owns 1,980,312 shares of the biotechnology company’s stock valued at $14,892,000 after purchasing an additional 1,444,907 shares in the last quarter. Nuveen LLC purchased a new position in BioCryst Pharmaceuticals during the first quarter valued at $10,677,000. Finally, Jupiter Asset Management Ltd. lifted its position in BioCryst Pharmaceuticals by 82.4% during the first quarter. Jupiter Asset Management Ltd. now owns 2,148,969 shares of the biotechnology company’s stock valued at $16,117,000 after purchasing an additional 971,040 shares in the last quarter. Institutional investors own 85.88% of the company’s stock.

About BioCryst Pharmaceuticals

BioCryst Pharmaceuticals, Inc, a biotechnology company, develops oral small-molecule and protein therapeutics to treat rare diseases. The company markets peramivir injection, an intravenous neuraminidase inhibitor for the treatment of acute uncomplicated influenza under the RAPIVAB, RAPIACTA, and PERAMIFLU names; and ORLADEYO, an oral serine protease inhibitor to treat hereditary angioedema.